Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients
Purpose Reduced temporal muscle thickness (TMT) has recently been postulated as a prognostic imaging marker and an objective tool to assess patients frailty in glioblastoma. Our aim is to investigate the correlation of TMT and systemic muscle loss to confirm that TMT is an adequate surrogate marker...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 2022-12, Vol.160 (3), p.611-618 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 618 |
|---|---|
| container_issue | 3 |
| container_start_page | 611 |
| container_title | Journal of neuro-oncology |
| container_volume | 160 |
| creator | ten Cate, Cecil Huijs, Sandra M. H. Willemsen, Anna C. H. Pasmans, Raphael C. O. S. Eekers, Daniëlle B. P. Zegers, Catharina M. L. Ackermans, Linda Beckervordersandforth, Jan van Raak, Elisabeth P. M. Anten, Monique H. M. E. Hoeben, Ann Postma, Alida A. Broen, Martinus P. G. |
| description | Purpose
Reduced temporal muscle thickness (TMT) has recently been postulated as a prognostic imaging marker and an objective tool to assess patients frailty in glioblastoma. Our aim is to investigate the correlation of TMT and systemic muscle loss to confirm that TMT is an adequate surrogate marker of sarcopenia in newly diagnosed glioblastoma patients.
Methods
TMT was assessed on preoperative MR-images and skeletal muscle area (SMA) was assessed at the third lumbar vertebra on preoperative abdominal CT-scans. Previous published TMT sex-specific cut-off values were used to classify patients as ‘patient at risk of sarcopenia’ or ‘patient with normal muscle status’. Correlation between TMT and SMA was assessed using Spearman’s rank correlation coefficient.
Results
Sixteen percent of the 245 included patients were identified as at risk of sarcopenia. The mean SMA of glioblastoma patients at risk of sarcopenia (124.3 cm
2
, SD 30.8 cm
2
) was significantly lower than the mean SMA of patients with normal muscle status (146.3 cm
2
, SD 31.1 cm
2
,
P
|
| doi_str_mv | 10.1007/s11060-022-04180-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9758090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2755001207</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-8fd956426a137eb51697b57b50b33251a27c7536e6d340bac5b2dc4f4c77a0a03</originalsourceid><addsrcrecordid>eNp9kUuLFDEUhYMoTjv6B1xIwI2b0ptXpWojSOMLBtwouAupVKonYyppk6qR_vfetmfGx0IIZHG-e-7jEPKUwUsGoF9VxqCFBjhvQLIOmu4e2TClRaOFFvfJBlirG9XLr2fkUa1XACC1YA_JmWhFLzXTG1K2uRQf7RJyonmixY-r8yNd_LzPxUY6r9VFT5fL4L4lXyu1aaT1UBEI7laNGYWQaPI_4oGOwe5SruiyiyEP0dYlz5busYlPS31MHkw2Vv_k5j8nX969_bz90Fx8ev9x--aicUrC0nTT2KtW8tYyof2gWNvrQeGDQQiumOXaaSVa345CwmCdGvjo5CSd1hYsiHPy-uS7X4fZjw5740JmX8Jsy8FkG8zfSgqXZpevTa9VB_3R4MWNQcnfV18XM4fqfIw2-bxWw_HMeEXBj-jzf9CrvJaE6yGlFADjoJHiJ8oVPFjx090wDMwxUnOK1GCk5lekpsOiZ3-ucVdymyEC4gRUlNLOl9-9_2P7E_gBruc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2755001207</pqid></control><display><type>article</type><title>Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients</title><source>SpringerNature Journals</source><creator>ten Cate, Cecil ; Huijs, Sandra M. H. ; Willemsen, Anna C. H. ; Pasmans, Raphael C. O. S. ; Eekers, Daniëlle B. P. ; Zegers, Catharina M. L. ; Ackermans, Linda ; Beckervordersandforth, Jan ; van Raak, Elisabeth P. M. ; Anten, Monique H. M. E. ; Hoeben, Ann ; Postma, Alida A. ; Broen, Martinus P. G.</creator><creatorcontrib>ten Cate, Cecil ; Huijs, Sandra M. H. ; Willemsen, Anna C. H. ; Pasmans, Raphael C. O. S. ; Eekers, Daniëlle B. P. ; Zegers, Catharina M. L. ; Ackermans, Linda ; Beckervordersandforth, Jan ; van Raak, Elisabeth P. M. ; Anten, Monique H. M. E. ; Hoeben, Ann ; Postma, Alida A. ; Broen, Martinus P. G.</creatorcontrib><description>Purpose
Reduced temporal muscle thickness (TMT) has recently been postulated as a prognostic imaging marker and an objective tool to assess patients frailty in glioblastoma. Our aim is to investigate the correlation of TMT and systemic muscle loss to confirm that TMT is an adequate surrogate marker of sarcopenia in newly diagnosed glioblastoma patients.
Methods
TMT was assessed on preoperative MR-images and skeletal muscle area (SMA) was assessed at the third lumbar vertebra on preoperative abdominal CT-scans. Previous published TMT sex-specific cut-off values were used to classify patients as ‘patient at risk of sarcopenia’ or ‘patient with normal muscle status’. Correlation between TMT and SMA was assessed using Spearman’s rank correlation coefficient.
Results
Sixteen percent of the 245 included patients were identified as at risk of sarcopenia. The mean SMA of glioblastoma patients at risk of sarcopenia (124.3 cm
2
, SD 30.8 cm
2
) was significantly lower than the mean SMA of patients with normal muscle status (146.3 cm
2
, SD 31.1 cm
2
,
P
< .001). We found a moderate association between TMT and SMA in the patients with normal muscle status (Spearman’s rho 0.521,
P <
.001), and a strong association in the patients at risk of sarcopenia (Spearman’s rho 0.678,
P
< .001).
Conclusion
Our results confirm the use of TMT as a surrogate marker of total body skeletal muscle mass in glioblastoma, especially in frail patients at risk of sarcopenia. TMT can be used to identify patients with muscle loss early in the disease process, which enables the implementation of adequate intervention strategies.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-022-04180-8</identifier><identifier>PMID: 36394717</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Brain cancer ; Computed tomography ; Glioblastoma ; Medicine ; Medicine & Public Health ; Musculoskeletal system ; Neurology ; Oncology ; Patients ; Sarcopenia ; Skeletal muscle ; Vertebrae</subject><ispartof>Journal of neuro-oncology, 2022-12, Vol.160 (3), p.611-618</ispartof><rights>The Author(s) 2022. corrected publications 2022, 2023</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. corrected publications 2022, 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2022, corrected publication 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-8fd956426a137eb51697b57b50b33251a27c7536e6d340bac5b2dc4f4c77a0a03</citedby><cites>FETCH-LOGICAL-c540t-8fd956426a137eb51697b57b50b33251a27c7536e6d340bac5b2dc4f4c77a0a03</cites><orcidid>0000-0002-8834-2202</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-022-04180-8$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-022-04180-8$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,27926,27927,41490,42559,51321</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36394717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ten Cate, Cecil</creatorcontrib><creatorcontrib>Huijs, Sandra M. H.</creatorcontrib><creatorcontrib>Willemsen, Anna C. H.</creatorcontrib><creatorcontrib>Pasmans, Raphael C. O. S.</creatorcontrib><creatorcontrib>Eekers, Daniëlle B. P.</creatorcontrib><creatorcontrib>Zegers, Catharina M. L.</creatorcontrib><creatorcontrib>Ackermans, Linda</creatorcontrib><creatorcontrib>Beckervordersandforth, Jan</creatorcontrib><creatorcontrib>van Raak, Elisabeth P. M.</creatorcontrib><creatorcontrib>Anten, Monique H. M. E.</creatorcontrib><creatorcontrib>Hoeben, Ann</creatorcontrib><creatorcontrib>Postma, Alida A.</creatorcontrib><creatorcontrib>Broen, Martinus P. G.</creatorcontrib><title>Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Purpose
Reduced temporal muscle thickness (TMT) has recently been postulated as a prognostic imaging marker and an objective tool to assess patients frailty in glioblastoma. Our aim is to investigate the correlation of TMT and systemic muscle loss to confirm that TMT is an adequate surrogate marker of sarcopenia in newly diagnosed glioblastoma patients.
Methods
TMT was assessed on preoperative MR-images and skeletal muscle area (SMA) was assessed at the third lumbar vertebra on preoperative abdominal CT-scans. Previous published TMT sex-specific cut-off values were used to classify patients as ‘patient at risk of sarcopenia’ or ‘patient with normal muscle status’. Correlation between TMT and SMA was assessed using Spearman’s rank correlation coefficient.
Results
Sixteen percent of the 245 included patients were identified as at risk of sarcopenia. The mean SMA of glioblastoma patients at risk of sarcopenia (124.3 cm
2
, SD 30.8 cm
2
) was significantly lower than the mean SMA of patients with normal muscle status (146.3 cm
2
, SD 31.1 cm
2
,
P
< .001). We found a moderate association between TMT and SMA in the patients with normal muscle status (Spearman’s rho 0.521,
P <
.001), and a strong association in the patients at risk of sarcopenia (Spearman’s rho 0.678,
P
< .001).
Conclusion
Our results confirm the use of TMT as a surrogate marker of total body skeletal muscle mass in glioblastoma, especially in frail patients at risk of sarcopenia. TMT can be used to identify patients with muscle loss early in the disease process, which enables the implementation of adequate intervention strategies.</description><subject>Brain cancer</subject><subject>Computed tomography</subject><subject>Glioblastoma</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Musculoskeletal system</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Patients</subject><subject>Sarcopenia</subject><subject>Skeletal muscle</subject><subject>Vertebrae</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kUuLFDEUhYMoTjv6B1xIwI2b0ptXpWojSOMLBtwouAupVKonYyppk6qR_vfetmfGx0IIZHG-e-7jEPKUwUsGoF9VxqCFBjhvQLIOmu4e2TClRaOFFvfJBlirG9XLr2fkUa1XACC1YA_JmWhFLzXTG1K2uRQf7RJyonmixY-r8yNd_LzPxUY6r9VFT5fL4L4lXyu1aaT1UBEI7laNGYWQaPI_4oGOwe5SruiyiyEP0dYlz5busYlPS31MHkw2Vv_k5j8nX969_bz90Fx8ev9x--aicUrC0nTT2KtW8tYyof2gWNvrQeGDQQiumOXaaSVa345CwmCdGvjo5CSd1hYsiHPy-uS7X4fZjw5740JmX8Jsy8FkG8zfSgqXZpevTa9VB_3R4MWNQcnfV18XM4fqfIw2-bxWw_HMeEXBj-jzf9CrvJaE6yGlFADjoJHiJ8oVPFjx090wDMwxUnOK1GCk5lekpsOiZ3-ucVdymyEC4gRUlNLOl9-9_2P7E_gBruc</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>ten Cate, Cecil</creator><creator>Huijs, Sandra M. H.</creator><creator>Willemsen, Anna C. H.</creator><creator>Pasmans, Raphael C. O. S.</creator><creator>Eekers, Daniëlle B. P.</creator><creator>Zegers, Catharina M. L.</creator><creator>Ackermans, Linda</creator><creator>Beckervordersandforth, Jan</creator><creator>van Raak, Elisabeth P. M.</creator><creator>Anten, Monique H. M. E.</creator><creator>Hoeben, Ann</creator><creator>Postma, Alida A.</creator><creator>Broen, Martinus P. G.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8834-2202</orcidid></search><sort><creationdate>20221201</creationdate><title>Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients</title><author>ten Cate, Cecil ; Huijs, Sandra M. H. ; Willemsen, Anna C. H. ; Pasmans, Raphael C. O. S. ; Eekers, Daniëlle B. P. ; Zegers, Catharina M. L. ; Ackermans, Linda ; Beckervordersandforth, Jan ; van Raak, Elisabeth P. M. ; Anten, Monique H. M. E. ; Hoeben, Ann ; Postma, Alida A. ; Broen, Martinus P. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-8fd956426a137eb51697b57b50b33251a27c7536e6d340bac5b2dc4f4c77a0a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Brain cancer</topic><topic>Computed tomography</topic><topic>Glioblastoma</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Musculoskeletal system</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Patients</topic><topic>Sarcopenia</topic><topic>Skeletal muscle</topic><topic>Vertebrae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ten Cate, Cecil</creatorcontrib><creatorcontrib>Huijs, Sandra M. H.</creatorcontrib><creatorcontrib>Willemsen, Anna C. H.</creatorcontrib><creatorcontrib>Pasmans, Raphael C. O. S.</creatorcontrib><creatorcontrib>Eekers, Daniëlle B. P.</creatorcontrib><creatorcontrib>Zegers, Catharina M. L.</creatorcontrib><creatorcontrib>Ackermans, Linda</creatorcontrib><creatorcontrib>Beckervordersandforth, Jan</creatorcontrib><creatorcontrib>van Raak, Elisabeth P. M.</creatorcontrib><creatorcontrib>Anten, Monique H. M. E.</creatorcontrib><creatorcontrib>Hoeben, Ann</creatorcontrib><creatorcontrib>Postma, Alida A.</creatorcontrib><creatorcontrib>Broen, Martinus P. G.</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ten Cate, Cecil</au><au>Huijs, Sandra M. H.</au><au>Willemsen, Anna C. H.</au><au>Pasmans, Raphael C. O. S.</au><au>Eekers, Daniëlle B. P.</au><au>Zegers, Catharina M. L.</au><au>Ackermans, Linda</au><au>Beckervordersandforth, Jan</au><au>van Raak, Elisabeth P. M.</au><au>Anten, Monique H. M. E.</au><au>Hoeben, Ann</au><au>Postma, Alida A.</au><au>Broen, Martinus P. G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>160</volume><issue>3</issue><spage>611</spage><epage>618</epage><pages>611-618</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Purpose
Reduced temporal muscle thickness (TMT) has recently been postulated as a prognostic imaging marker and an objective tool to assess patients frailty in glioblastoma. Our aim is to investigate the correlation of TMT and systemic muscle loss to confirm that TMT is an adequate surrogate marker of sarcopenia in newly diagnosed glioblastoma patients.
Methods
TMT was assessed on preoperative MR-images and skeletal muscle area (SMA) was assessed at the third lumbar vertebra on preoperative abdominal CT-scans. Previous published TMT sex-specific cut-off values were used to classify patients as ‘patient at risk of sarcopenia’ or ‘patient with normal muscle status’. Correlation between TMT and SMA was assessed using Spearman’s rank correlation coefficient.
Results
Sixteen percent of the 245 included patients were identified as at risk of sarcopenia. The mean SMA of glioblastoma patients at risk of sarcopenia (124.3 cm
2
, SD 30.8 cm
2
) was significantly lower than the mean SMA of patients with normal muscle status (146.3 cm
2
, SD 31.1 cm
2
,
P
< .001). We found a moderate association between TMT and SMA in the patients with normal muscle status (Spearman’s rho 0.521,
P <
.001), and a strong association in the patients at risk of sarcopenia (Spearman’s rho 0.678,
P
< .001).
Conclusion
Our results confirm the use of TMT as a surrogate marker of total body skeletal muscle mass in glioblastoma, especially in frail patients at risk of sarcopenia. TMT can be used to identify patients with muscle loss early in the disease process, which enables the implementation of adequate intervention strategies.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36394717</pmid><doi>10.1007/s11060-022-04180-8</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8834-2202</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2022-12, Vol.160 (3), p.611-618 |
| issn | 0167-594X 1573-7373 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9758090 |
| source | SpringerNature Journals |
| subjects | Brain cancer Computed tomography Glioblastoma Medicine Medicine & Public Health Musculoskeletal system Neurology Oncology Patients Sarcopenia Skeletal muscle Vertebrae |
| title | Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T18%3A46%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20of%20reduced%20temporal%20muscle%20thickness%20and%20systemic%20muscle%20loss%20in%20newly%20diagnosed%20glioblastoma%20patients&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=ten%20Cate,%20Cecil&rft.date=2022-12-01&rft.volume=160&rft.issue=3&rft.spage=611&rft.epage=618&rft.pages=611-618&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-022-04180-8&rft_dat=%3Cproquest_pubme%3E2755001207%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2755001207&rft_id=info:pmid/36394717&rfr_iscdi=true |